IP Library Granted Patent US 8,187,591
Granted Patent B2
US 8,187,591 · App. 12/681,884 · Granted May 29, 2012

Methods of treating coagulopathy

Assignee: The Regents of the University of California
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,187,591
App. No.
12/681,884
Granted
May 29, 2012
Kind
B2
Abstract

The invention provides compositions and methods for enhancing clearance of coagulation factors {e.g., VWF) and platelets from the blood stream of a patient in need thereof. The methods comprise administering to the patient a therapeutically effective amount of an agent that increases clearance of coagulation factors or platelets. Such an agent can be, for example, a neuraminidase.

Claims (14)

1. A method of treating coagulopathy in a patient, the method comprising administering to the patient a therapeutically effective amount of a neuraminidase polypeptide that increases clearance of coagulation factors or platelets.

2. The method of claim 1 , wherein the coagulopathy is associated with infection by a pathogen.

3. The method of claim 2 , wherein the pathogen lacks neuraminidase activity.

4. The method of claim 2 , wherein the pathogen has neuraminidase activity.

5. The method of claim 2 , wherein the pathogen is a bacterium.

6. The method of claim 5 , wherein the bacterium is Streptococcus pneumoniae.

7. The method of claim 1 , wherein the coagulopathy is associated with carcinoma, massive tissue injury, snake bite, heat stroke, or liver disease.

8. The method of claim 1 , wherein the coagulopathy is disseminated intravascular coagulation (DIC).

9. The method of claim 1 , wherein the neuraminidase is a bacterial neuraminidase.

10. The method of claim 9 , wherein the neuraminidase is from Arthrobacter ureafaciens.

11. The method of claim 9 , wherein the neuraminidase is from Vibrio cholerae.

12. The method of claim 1 , further comprising administering to the patient a sialyltransferase inhibitor.

13. The method of claim 12 , wherein the sialyltransferase inhibitor inhibits the sialyltransferase ST3Gal IV.

14. The method of claim 12 , wherein the sialyltransferase inhibitor is an analog of a sialyltransferase.

Assignments (3)
CONFIRMATORY LICENSE Recorded Oct 22, 2012
From: UNIVERSITY OF CALIFORNIA SAN DIEGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 029164/0724 →
CONFIRMATORY LICENSE Recorded Aug 22, 2012
From: UNIVERSITY OF CALIFORNIA SAN DIEGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 028826/0691 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2010
From: MARTH, JAMEY D.; GREWAL, PRABHJIT KAUR
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 024405/0202 →
Continuity (2)
Provisional Application 60979366 · Oct 11, 2007
Related Publication 20100285028A1 · Nov 11, 2010